Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals

Abstract

BackgroundBecause of the vulnerability and frailty of elderly adults, clinical drug development has traditionally been biased towards young and middle-aged adults. Recent efforts have begun to incorporate data from paediatric investigations. Nevertheless, the elderly often remain underrepresented in clinical trials, even though persons aged 65 years and older receive the majority of drug prescriptions. Consequently, a knowledge gap exists with regard to pharmacokinetic (PK) and pharmacodynamic (PD) responses in elderly subjects, leaving the safety and efficacy of medicines for this population unclear.ObjectivesThe goal of this study was to extend a physiologically based pharmacokinetic (PBPK) model for adults to encompass the full course of healthy aging through to the age of 100 years, to support dose selection and improve pharmacotherapy for the elderly age group.MethodsFor parameterization of the PBPK model for healthy aging individuals, the literature was scanned for anthropometric and physiological data, which were consolidated and incorporated into the PBPK software PK-Sim®. Age-related changes that occur from 65 to 100 years of age were the main focus of this work. For a sound and continuous description of an aging human, data on anatomical and physiological changes ranging from early adulthood to old age were included. The capability of the PBPK approach to predict distribution and elimination of drugs was verified using the test compounds morphine and furosemide, administered intravenously. Both are cleared by a single elimination pathway. PK parameters for the two compounds in younger adults and elderly individuals were obtained from the literature. Matching virtual populations—with regard to age, sex, anthropometric measures and dosage—were generated. Profiles of plasma drug concentrations over time, volume of distribution at steady state (V ss) values and elimination half-life (t ½) values from the literature were compared with those predicted by PBPK simulations for both younger adults and the elderly.ResultsFor most organs, the age-dependent information gathered in the extensive literature analysis was dense. In contrast, with respect to blood flow, the literature study produced only sparse data for several tissues, and in these cases, linear regression was required to capture the entire elderly age range. On the basis of age-informed physiology, the predicted PK profiles described age-associated trends well. The root mean squared prediction error for the prediction of plasma concentrations of furosemide and morphine in the elderly were improved by 32 and 49 %, respectively, by use of age-informed physiology. The majority of the individual V ss and t ½ values for the two model compounds, furosemide and morphine, were well predicted in the elderly population, except for long furosemide half-lifes.ConclusionThe results of this study support the feasibility of using a knowledge-driven PBPK aging model that includes the elderly to predict PK alterations throughout the entire course of aging, and thus to...

Predictive Pediatric Modeling and Simulation Using Ontogeny Information

“…Owing to this feature, PBPK models are generic because the system‐specific parameters (as well as the compound‐specific parameter values) can be exchanged, allowing the translation of these models to a population with a different physiology. For example, numerous PBPK models were previously built for special populations by replacing the system‐specific parameters of adults with those for preterm neonates, children, pregnant women, or elderly individuals …”

Applied Concepts in PBPK Modeling: How to Extend an Open Systems Pharmacology Model to the Special Population of Pregnant Women

“…Potential research questions requiring the inclusion of new compartments could focus on, for example, ophthalmic medicines, in which the drug concentrations in the eye need to be modeled or on oncologic substances, in which the drug concentration needs to be predicted in the tumor tissue. However, the presented conceptual workflow—establishment of a model for reference subjects using in vitro and clinical data, evaluation of this model against in vivo data, substitution of the system‐specific parameter values with values specific for other individuals, here, pregnancy‐specific values available as prior knowledge—is platform‐independent and common practice in PBPK research . Ideally, the model structures, parameterizations, and scaling workflows are comparable across different PBPK platforms and similar prediction results are obtained regardless of which platform is used as has recently been discussed in more detail elsewhere .…”

“…Intrinsic factors (e.g., age, gender, weight, pregnancy, and disease) or extrinsic factors (e.g., concomitant intake of drugs or herbal products, diet, and smoking) can thereby be incorporated in the model and their effect on drug disposition investigated in silico . Several databases have been published in this context that support the incorporation of population‐specific physiological values in PBPK models, in particular for preterm neonates, children, pregnant women, or elderly individuals …”

Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact

“…A major advantage of PBPK modeling is the ability to integrate knowledge from human physiology, drug physicochemical properties, and enzyme and protein variability in patients to generate drug PK predictions in a given population or individual. PBPK models also have been applied broadly to guide individual dosing in special populations . PBPK models can also support precision dosing in a variety of clinical settings, including patients with organ dysfunction, patients coadministered enzyme inhibitors and inducers, and populations with certain genetic variations.…”